1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Cuba Pharmaceuticals and Healthcare Report Q2 2016

Cuba Pharmaceuticals and Healthcare Report Q2 2016

  • February 2016
  • -
  • Business Monitor International
  • -
  • 66 pages

BMI View: The special development zone will allow Cuba to have greater openness in parts of its statewithout the danger of risking its entire system under the 'threat' of the free-market. The Chinese style (morefree market-oriented and flexible) governmental measures in the special development zone will providesignificant investment opportunities for pharmaceutical companies.

Headline Expenditure Projections

- Pharmaceuticals: CUP1.51bn (USD1.51bn) in 2015 to CUP1.61bn (USD1.61bn) in 2016; +6.5% inlocal currency terms and US dollar terms. Forecasts have been maintained from Q116.

• Healthcare: CUP7.62bn (USD7.62bn) in 2014 to CUP8.01bn (USD8.01bn) in 2016; +5.1% in localcurrency terms and US dollar terms. Forecasts have been maintained from Q415.

Table Of Contents

Cuba Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Cuba 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Cuba 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Cuba 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Cuba 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Cuba 2012-2020) 16
Pharmaceutical Trade Forecast 17
Table: Pharmaceutical Trade Data And Forecasts (Cuba 2014-2020) 20
Industry Risk Reward Index 21
Americas Risk/Reward Index 21
Cuba Risk/Reward Index 27
Rewards 27
Risk 27
Regulatory Review 29
Intellectual Property Issues 31
Pricing Regime 32
Reimbursement Regime 32
Market Overview 34
Healthcare Sector 35
Table: Healthcare Resources (Cuba 2010-2015) 36
Table: Healthcare Personnel (Cuba 2010-2015) 37
Table: Healthcare Activity (Cuba 2010-2015) 37
Research and Development 37
Clinical Trials 39
Epidemiology 40
Competitive Landscape 43
Research-Based Industry 43
Table: Biotechnology, Pharmaceutical and Healthcare's Members of CAMARACUBA, 2010 44
Table: Licensed Local Pharmaceutical Producers, April 2011 46
Table: Foreign Producers with GMP Certificates, April 2011 51
Generic Drugmakers 53
Pharmaceutical Distribution 54
Pharmaceutical Retail Sector 54
Demographic Forecast 55
Table: Population Headline Indicators (Cuba 1990-2025) 56
Table: Key Population Ratios (Cuba 1990-2025) 56
Table: Urban/Rural Population and Life Expectancy (Cuba 1990-2025) 57
Table: Population By Age Group (Cuba 1990-2025) 57
Table: Population By Age Group % (Cuba 1990-2025) 58
Glossary 60
Methodology 62
Pharmaceutical Expenditure Forecast Model 62
Healthcare Expenditure Forecast Model 62
Notes On Methodology 63
Risk/Reward Index Methodology 64
Index Overview 65
Table: Pharmaceutical Risk/Reward Index Indicators 65
Indicator Weightings 66

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.